Did China’s At‑Home LEQEMBI Review Just Shift Biogen’s (BIIB) Alzheimer’s Care Investment Narrative?
Biogen and Eisai previously announced that China’s National Medical Products Administration accepted their Biologics License Application for a subcutaneous,




